Advertising Disclaimer
Published online September 7, 2009
PEDIATRICS Vol. 124 No. 6 December 2009, pp. 1694-1701 (doi:10.1542/peds.2009-2345)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View eLetters
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Infectious Disease & Immunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

POLICY STATEMENT

Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections

Committee on Infectious Diseases

Palivizumab was licensed in June 1998 by the US Food and Drug Administration for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients who are at increased risk of severe disease. Safety and efficacy have been established for infants born at or before 35 weeks' gestation with or without chronic lung disease of prematurity and for infants and children with hemodynamically significant heart disease. The American Academy of Pediatrics (AAP) published a policy statement on the use of palivizumab in November 1998 (American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 1998;102[5]:1211–1216) and revised it in December 2003 (American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 2003;112[6 pt 1]:1442–1446), and an AAP technical report on palivizumab was published in 2003 (Meissner HC, Long SS; American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 2003;112[6 pt 1]:1447–1452). On the basis of the availability of additional data regarding seasonality of RSV disease as well as the limitations in available data on risk factors for identifying children who are at increased risk of serious RSV lower respiratory tract disease, AAP recommendations for immunoprophylaxis have been updated in an effort to ensure optimal balance of benefit and cost from this expensive intervention. This statement updates and replaces the 2003 AAP statement and the 2006 Red Book and is consistent with the 2009 Red Book recommendations.

Key Words: RSV bronchiolitis • palivizumab • immunoprophylaxis

Abbreviations: CDC—Centers for Disease Control and Prevention • RSV—respiratory syncytial virus • CHD—congenital heart disease • CLD—chronic lung disease of prematurity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
G. A. Rossi, M. Silvestri, and M. Lanari
Should the American Academy of Pediatrics Respiratory Syncytial Virus Guidelines Be Modified?
Pediatrics, April 1, 2010; 125(4): e1021 - e1021.
[Full Text] [PDF]

Home page
 PediatricsHome page
In Reply
Pediatrics, April 1, 2010; 125(4): e1022 - e1023.
[Full Text] [PDF]

Home page
 PediatricsHome page
H. C. Meissner, J. A. Bocchini Jr, M. T. Brady, C. B. Hall, D. W. Kimberlin, and L. K. Pickering
The Role of Immunoprophylaxis in the Reduction of Disease Attributable to Respiratory Syncytial Virus
Pediatrics, December 1, 2009; 124(6): 1676 - 1679.
[Full Text] [PDF]

eLetters:

Read all eLetters

Should the RSV AAP guidelines be modified ?
Giovanni A. Rossi, et al.
Pediatrics Online, 29 Dec 2009 [Full text]
AAP Guidelines for Use of Palivizumab
Committee on Infectious Diseases
Pediatrics Online, 21 Jan 2010 [Full text]